ARRY

Array Technologies

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Technology

industry

Solar

Exchange

Nasdaq

County of HQ

France

Next Earnings Date

05/05/26

Business Summary

DBV Technologies is a clinical-stage biotechnology company focused on developing immunotherapy treatments, generating cash primarily through capital raises rather than commercialized product revenue. Its moat, if successful, would stem from proprietary platforms and clinical data exclusivity that can command pricing power upon regulatory approval. In biotech, defensibility comes from patents, regulatory barriers, and specialized scientific expertise rather than scale economics. The company’s ability to convert research into approved therapies is the single determinant of long-term cash generation, making its competitive advantage entirely execution-dependent.

VALUATION

P/E

-

Market Cap ($M USD)

$1,095

Forward P/E

8.3

PEG

4.4

PRICE TO SALES

0.9

PRICE TO BOOK

-

EV / EBITDA

45.9

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.73

Next Year EPS Growth Estimate

$0.86

Next Year Revenue Growth Estimate

8.20%

Return on Equity (ROE)

-43.00%

Operating Margin

5.70%

Debt-to-Equity

2.9

Piotroski F-Score

4

Altman Z-Score

1.6

Return on Invested Capital (ROIC)

-8.20%%

Current Ratio

2.3

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At a $1,235M market cap, DBVT is a pure high-risk biotech profile with no earnings support, reflected in a negative EPS of -7.5 and an expected -5.25 next year, leaving both P/E and Forward P/E nonexistent. The operating margin of -87.10% and ROIC of -138.70% confirm a business still deeply cash consumptive, yet the Altman Z-Score of 7.8 and a current ratio of 3.7 signal strong balance sheet resilience and low near-term bankruptcy risk. The market is not mispricing profitability—it is correctly discounting it—but it may be underappreciating financial survivability. This is not a growth compounder; it is a balance-sheet-backed clinical optionality vehicle.

AI Exposure / Tech Reliance

As a biotechnology company, DBVT sits in an industry that increasingly integrates AI into drug discovery, trial design, and biomarker targeting. While no specific AI metrics are provided, the sector’s reliance on data-driven development inherently aligns it with technological acceleration. The key question is execution efficiency, not digital adoption, given its deeply negative operating profile.

The Bull Case

A value-oriented biotech investor could argue that the combination of a 7.8 Altman Z-Score and a 3.7 current ratio dramatically reduces insolvency risk despite steep losses. Institutional ownership at 39.99% suggests meaningful professional participation, and a Piotroski F-Score of 4, while not strong, indicates middling financial stability rather than collapse. The projected improvement in EPS from -7.5 to -5.25 implies loss contraction, and the extremely high reported Return on Equity of 2366.70%—though likely distorted by capital structure—signals equity leverage to any operational inflection. With a Price/Book of 7.2, investors are clearly paying for intellectual property and pipeline potential rather than tangible assets, which is typical in biotech turnarounds.

The Bear Case

The bear case is straightforward and brutal: -87.10% operating margins and -138.70% ROIC represent structural value destruction, not temporary weakness. Sales Growth Next Year of -$0.23 indicates no visible revenue acceleration, and the absence of meaningful earnings metrics (no P/E, no Forward P/E, no PEG Forward) eliminates any GARP framework justification. EPS remains deeply negative, and there is no dividend support beyond a negligible 0.1 TTM yield with a 0 five-year average. With no Debt/Equity data provided and no Short % transparency, investors are operating with incomplete leverage and sentiment signals—dangerous in a speculative biotech environment.

Market Sentiment & Smart Money

Short Interest %

17.70%

Analyst Consensus

2.13

Average Analyst Price Target

$9.73

Institutional Ownership %

135.40%

1-Year Beta

2.17

Insider Buying % (6 Mo)

0.60%%

Distance to 52-Week High

58.50%%

Distance to 52-Week Low

180.10%%